162 related articles for article (PubMed ID: 7558140)
1. Shedding and enrichment of the glycolipid-anchored complement lysis inhibitor protectin (CD59) into milk fat globules.
Hakulinen J; Meri S
Immunology; 1995 Jul; 85(3):495-501. PubMed ID: 7558140
[TBL] [Abstract][Full Text] [Related]
2. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells.
Hakulinen J; Meri S
Lab Invest; 1994 Dec; 71(6):820-7. PubMed ID: 7528832
[TBL] [Abstract][Full Text] [Related]
3. Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction.
Väkevä A; Laurila P; Meri S
Lab Invest; 1992 Nov; 67(5):608-16. PubMed ID: 1279272
[TBL] [Abstract][Full Text] [Related]
4. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.
Mäenpää A; Junnikkala S; Hakulinen J; Timonen T; Meri S
Am J Pathol; 1996 Apr; 148(4):1139-52. PubMed ID: 8644856
[TBL] [Abstract][Full Text] [Related]
5. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
[TBL] [Abstract][Full Text] [Related]
6. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues.
Meri S; Waldmann H; Lachmann PJ
Lab Invest; 1991 Nov; 65(5):532-7. PubMed ID: 1721667
[TBL] [Abstract][Full Text] [Related]
7. Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.
Brasoveanu LI; Fonsatti E; Visintin A; Pavlovic M; Cattarossi I; Colizzi F; Gasparollo A; Coral S; Horejsi V; Altomonte M; Maio M
J Clin Invest; 1997 Sep; 100(5):1248-55. PubMed ID: 9276743
[TBL] [Abstract][Full Text] [Related]
8. Demonstration of HLA-DR-like antigens on milk fat globule membranes.
Wiman K; Curman B; Trägårdh L; Peterson PA
Eur J Immunol; 1979 Mar; 9(3):190-5. PubMed ID: 376317
[TBL] [Abstract][Full Text] [Related]
9. High-density lipoproteins can act as carriers of glycophosphoinositol lipid-anchored CD59 in human plasma.
Väkevä A; Jauhiainen M; Ehnholm C; Lehto T; Meri S
Immunology; 1994 May; 82(1):28-33. PubMed ID: 7519171
[TBL] [Abstract][Full Text] [Related]
10. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
[TBL] [Abstract][Full Text] [Related]
11. Expression of the complement regulatory protein CD59 on human spermatozoa: characterization and role in gametic interaction.
Fenichel P; Cervoni F; Hofmann P; Deckert M; Emiliozzi C; Hsi BL; Rossi B
Mol Reprod Dev; 1994 Jul; 38(3):338-46. PubMed ID: 7522480
[TBL] [Abstract][Full Text] [Related]
12. CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis.
Brooimans RA; Van der Ark AA; Tomita M; Van Es LA; Daha MR
Eur J Immunol; 1992 Mar; 22(3):791-7. PubMed ID: 1372260
[TBL] [Abstract][Full Text] [Related]
13. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
Tomlinson S; Whitlow MB; Nussenzweig V
J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
[TBL] [Abstract][Full Text] [Related]
15. Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59.
Husler T; Lockert DH; Sims PJ
Biochemistry; 1996 Mar; 35(10):3263-9. PubMed ID: 8605162
[TBL] [Abstract][Full Text] [Related]
16. Mapping the regions of the complement inhibitor CD59 responsible for its species selective activity.
Yu J; Dong S; Rushmere NK; Morgan BP; Abagyan R; Tomlinson S
Biochemistry; 1997 Aug; 36(31):9423-8. PubMed ID: 9235986
[TBL] [Abstract][Full Text] [Related]
17. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
Meri S; Morgan BP; Davies A; Daniels RH; Olavesen MG; Waldmann H; Lachmann PJ
Immunology; 1990 Sep; 71(1):1-9. PubMed ID: 1698710
[TBL] [Abstract][Full Text] [Related]
18. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells.
Junnikkala S; Hakulinen J; Meri S
Eur J Immunol; 1994 Mar; 24(3):611-5. PubMed ID: 7510237
[TBL] [Abstract][Full Text] [Related]
19. Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted.
van den Berg CW; Morgan BP
J Immunol; 1994 Apr; 152(8):4095-101. PubMed ID: 7511666
[TBL] [Abstract][Full Text] [Related]
20. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV).
Spear GT; Lurain NS; Parker CJ; Ghassemi M; Payne GH; Saifuddin M
J Immunol; 1995 Nov; 155(9):4376-81. PubMed ID: 7594597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
